To address whether the reduction in p53 phosphorylation upon PHD1 silencing also holds true upon different chemotherapeutics clinically used in CRC treatment, we exposed HCT116 to either SN-38 or oxaliplatin. The gene discussed is EGLN2; the disease is colorectal carcinoma.